Tedatioxetine
Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]
![]() | |
![]() | |
| Clinical data | |
|---|---|
| Other names | Lu AA24530; Lu-AA-24530 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C18H21NS |
| Molar mass | 283.43 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[2][3][4][5]
As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]
On May 10, 2016, all work on tedatioxetine stopped.[8]
A Sino Patent manages to show that there has been interest in this compound outside of Lundbeck: WO 2015090160
See also
References
- Daniel Beaulieu for First Word Pharma. September 5th, 2007 Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs
- "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014.
- Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
- Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
- "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech".
- "Pipeline of Lundbeck". Retrieved 25 August 2013.
- UK Medicines Information Tedatioxetine entry in UKMI. Page accessed January 20, 2016
- "Tedatioxetine - AdisInsight". adisinsight.springer.com. Retrieved 2016-06-09.
External links
Adrenergic receptor modulators | |
|---|---|
| α1 |
|
| α2 |
|
| β |
|
| DAT (DRIs) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NET (NRIs) |
| ||||||||||||||
| SERT (SRIs) |
| ||||||||||||||
| VMATs |
| ||||||||||||||
| Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins | |||||||||||||||
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||

